Purpose of reviewBased on the recent data of the DA VINCI study, it is clear that, besides utilization of statins, there is a need to increase non-statin lipid lowering approaches to reduce the cardiovascular burden in patients at highest risk.Recent findingsFor hypercholesterolemia, the small synthetic molecule bempedoic acid has the added benefit of selective liver activation, whereas inclisiran, a hepatic inhibitor of the PCSK9 synthesis, has comparable effects with PCSK9 monoclonal antibodies. For hypertriglyceridemia, cardiovascular benefit has been achieved by the use of icosapent ethyl, whereas results with pemafibrate, a selective agonist of PPAR-alpha, are eagerly awaited. In the era of RNA-based therapies, new options are offered to dramatically reduce levels of lipoprotein(a) (APO(a)L-RX) and of triglycerides (ANGPTL3L(RX) and APOCIII-L-Rx).SummaryDespite the demonstrated benefits of statins, a large number of patients still remain at significant risk because of inadequate LDL-C reduction or elevated blood triglyceride-rich lipoproteins or lipoprotein(a). The area of lipid modulating agents is still ripe with ideas and major novelties are to be awaited in the next few years.
Lipid Lowering Drugs: Present Status and Future Developments / M. Ruscica, N. Ferri, R.D. Santos, C.R. Sirtori, A. Corsini. - In: CURRENT ATHEROSCLEROSIS REPORTS. - ISSN 1523-3804. - 23:5(2021 May), pp. 17.1-17.13. [10.1007/s11883-021-00918-3]
Lipid Lowering Drugs: Present Status and Future Developments
M. Ruscica
Primo
Writing – Review & Editing
;C.R. Sirtori;A. Corsini
Writing – Review & Editing
2021
Abstract
Purpose of reviewBased on the recent data of the DA VINCI study, it is clear that, besides utilization of statins, there is a need to increase non-statin lipid lowering approaches to reduce the cardiovascular burden in patients at highest risk.Recent findingsFor hypercholesterolemia, the small synthetic molecule bempedoic acid has the added benefit of selective liver activation, whereas inclisiran, a hepatic inhibitor of the PCSK9 synthesis, has comparable effects with PCSK9 monoclonal antibodies. For hypertriglyceridemia, cardiovascular benefit has been achieved by the use of icosapent ethyl, whereas results with pemafibrate, a selective agonist of PPAR-alpha, are eagerly awaited. In the era of RNA-based therapies, new options are offered to dramatically reduce levels of lipoprotein(a) (APO(a)L-RX) and of triglycerides (ANGPTL3L(RX) and APOCIII-L-Rx).SummaryDespite the demonstrated benefits of statins, a large number of patients still remain at significant risk because of inadequate LDL-C reduction or elevated blood triglyceride-rich lipoproteins or lipoprotein(a). The area of lipid modulating agents is still ripe with ideas and major novelties are to be awaited in the next few years.File | Dimensione | Formato | |
---|---|---|---|
Massimiliano Ruscica.pdf
accesso aperto
Descrizione: Online first
Tipologia:
Publisher's version/PDF
Dimensione
677.96 kB
Formato
Adobe PDF
|
677.96 kB | Adobe PDF | Visualizza/Apri |
Ruscica2021_Article_LipidLoweringDrugsPresentStatu.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
674.01 kB
Formato
Adobe PDF
|
674.01 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.